J
John T. M. Plukker
Researcher at University Medical Center Groningen
Publications - 196
Citations - 8405
John T. M. Plukker is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Cancer & Esophageal cancer. The author has an hindex of 46, co-authored 187 publications receiving 7062 citations. Previous affiliations of John T. M. Plukker include Drug Abuse Resistance Education & University of Groningen.
Papers
More filters
Journal ArticleDOI
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more
TL;DR: Long-term follow-up confirms the overall survival benefits for neoadjuvant chemoradiotherapy in patients with clinically resectable, locally advanced cancer of the oesophagus or Oesophagogastric junction and shows a significant increase in 5-year overall survival.
Journal ArticleDOI
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors
Jan Willem B. de Groot,Thera P. Links,John T. M. Plukker,Cornelis J.M. Lips,Robert M. W. Hofstra +4 more
TL;DR: Evidence is provided that RET is indeed a potential target for selective cancer therapy, and a clinically useful therapeutic option for treating patients with RET-associated cancer is still not available.
Journal ArticleDOI
Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy. Systematic review
Marinke Westerterp,Henderik L van Westreenen,Johannes B. Reitsma,Otto S. Hoekstra,Jaap Stoker,Paul Fockens,Pieter L Jager,Berthe L. F. van Eck-Smit,John T. M. Plukker,J. Jan B. van Lanschot,Gerrit W. Sloof +10 more
TL;DR: CT has poor accuracy for assessment of response to neoadjuvant therapy in patients with esophageal cancer, while Endoscopic US and FDG PET have equivalent good accuracy, but endoscopic US is not always feasible after chemotherapy and radiation therapy.
Journal ArticleDOI
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Ben M Eyck,J. Jan B. van Lanschot,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Berend J van der Wilk,Joel Shapiro,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Geert-Jan Creemers,Cornelis J. A. Punt,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Maurice J.C. van der Sangen,Tom Rozema,Fiebo J. W. ten Kate,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ewout W. Steyerberg,Ate van der Gaast +33 more
TL;DR: Chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resusceptible cancer in this paper.
Journal ArticleDOI
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
Carla Oliveira,Jantine L. Westra,Diego Arango,Miina Ollikainen,Enric Domingo,Ana Ferreira,Sérgia Velho,Renee C. Niessen,Kristina Lagerstedt,Pia Alhopuro,Päivi Laiho,Isabel Veiga,Manuel R. Teixeira,Marjolijn J. L. Ligtenberg,Jan H. Kleibeuker,Rolf H. Sijmons,John T. M. Plukker,Kohzoh Imai,Pedro Lage,Richard Hamelin,Cristina Albuquerque,Simó Schwartz,Annika Lindblom,Päivi Peltomäki,Hiroyuki Yamamoto,Lauri A. Aaltonen,Raquel Seruca,Robert M.W. Hofstra +27 more
TL;DR: It is shown that depending on the genetic/epigenetic mechanism leading to MSI-H, the outcome in terms of oncogenic activation may be different, reinforcing the idea that HNPCC, sporadic MSI-h (depending on the hMLH1 status) and MSS CRCs, may target distinct kinases within the RAS/RAF/MAPK pathway.